Lv7
4238 积分 2022-09-22 加入
Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial
10天前
已完结
Safety and efficacy of elranatamab in patients with relapsed and/or refractory immunoglobulin light-chain amyloidosis
12天前
已完结
Systemic Amyloidosis Recognition, Prognosis, and Therapy
14天前
已完结
Inhibition of JNK Signaling Overcomes Cancer-Associated Fibroblast-Mediated Immunosuppression and Enhances the Efficacy of Immunotherapy in Bladder Cancer
19天前
已完结
The immune contexture in human tumours: impact on clinical outcome
19天前
已完结
Reinventing type 2 immunity in cancer
20天前
已完结
Emerging role for thymic stromal lymphopoietin–responsive regulatory T cells in colorectal cancer progression in humans and mice
20天前
已完结
Interleukin-33 in tumorigenesis, tumor immune evasion, and cancer immunotherapy
22天前
已完结
TSLP promotes GATA3-expressing effector regulatory T cells via DC2 derived from transitional DCs
22天前
已完结
Cancer immune evasion, immunoediting and intratumour heterogeneity
22天前
已完结
皖公网安备34019202002308
